Systematic Assessment of the Ability of the Number and Percentage of Positive Biopsy Cores to Predict Pathologic Stage and Biochemical Recurrence after Radical Prostatectomy

European Urology

Volumn 52, Issue 3, 2007, Pages 733-745

  Briganti, Alberto ^b   Chun, Felix K H ^c   Hutterer, Georg C ^a,d   Gallina, Andrea ^b   Shariat, Shahrokh F ^e   Salonia, Andrea ^b   Scattoni, Vincenzo ^b   Valiquette, Luc ^f   Montorsi, Francesco ^b   Rigatti, Patrizio ^b   Graefen, Markus ^c   Huland, Hartwig ^c   Karakiewicz, Pierre I ^a,f  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Number of prostate biopsy cores; Percentage of positive cores; Prediction; Prostate cancer

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RADICAL RETROPUBIC PROSTATECTOMY;

BIOPSY; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE PERIOD; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 34547233699     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.02.054     Document Type: Article

References (23)

1. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766-771
2. Kattan M.W., Stapleton A.M., Wheeler T.M., et al. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 79 (1997) 528-537
3. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer: a multi institutional update. JAMA 277 (1997) 1445-1451
4. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 17 (1999) 168-172
5. Graefen M., Noldus J., Pichlmeier U., et al. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics. Eur Urol 36 (1999) 21-30
6. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18 (2000) 1164-1172
7. Sebo T.J., Cheville J.C., Riehle D.L., et al. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. Cancer 91 (2001) 2196-2204
8. Briganti A., Chun F.K., Salonia A., et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 49 (2006) 1019-1026
9. Chun F.K., Karakiewicz P.I., Briganti A., et al. Prostate cancer nomograms: an update. Eur Urol 50 (2006) 914-926
10. Egawa S., Suyama K., Matsumoto K., et al. Improved predictability of extracapsular extension and seminal vesicle involvement based on clinical and biopsy findings in prostate cancer in Japanese men. Urology 52 (1998) 433-440
11. Wills M.L., Sauvageot J., Partin A.W., et al. Ability of sextant biopsies to predict radical prostatectomy stage. Urology 51 (1998) 759-764
12. Freedland S.J., Aronson W.J., Csathy G.S., et al., SEARCH Database Study Group. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database. Urology 61 (2003) 742-747
13. Yoon J.H., Chen M.H., Renshaw A.A., et al. Predictive factor analysis as the basis for the clinical utility of percent positive prostate biopsies in patients with intermediate-risk prostate cancer. Urology 60 (2002) 454-457
14. Ochiai A., Troncoso P., Chen M.E., et al. The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management. J Urol 174 (2005) 2164-2168
15. Graefen M., Ohori M., Karakiewicz P.I., et al. Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. J Urol 171 (2004) 200-203
16. Guzzo T.J., Vira M., Wang Y., et al. Preoperative parameters, including percent positive biopsy, in predicting seminal vesicle involvement in patients with prostate cancer. J Urol 175 (2006) 518-521
17. Lotan Y., Shariat S.F., Khoddami S.M., et al. The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy. J Urol 171 (2004) 2209-2214
18. Quinn D.I., Henshall S.M., Brenner P.C., et al. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion. Cancer 97 (2003) 1884-1893
19. Gancarczyk K.J., Wu H., McLeod D.G., et al. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. Urology 61 (2003) 589-595
20. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Combination of the preoperative PSA level, biopsy Gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology 55 (2000) 572-577
21. Freedland S.J., Csathy G.S., Dorey F., et al. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol 167 (2002) 516-520
22. Mian B.M., Lehr D.J., Moore C.K., et al. Role of prostate biopsy schemes in accurate prediction of Gleason scores. Urology 67 (2006) 379-383
23. Montironi R., Vela-Navarrete R., Lopez-Beltran A., et al. 2005 update on pathology of prostate biopsies with cancer. Eur Urol 49 (2006) 441-447